I found the field of Pharmacology & Pharmacy; Chemistry very interesting. Saw the article Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model published in 2019.0. SDS of cas: 500-22-1, Reprint Addresses Lim, SM; Pae, AN (corresponding author), Korea Inst Sci & Technol, Convergence Res Ctr Diag Treatment & Care Syst De, 5,Hwarang Ro 14 Gil, Seoul 02792, South Korea.. The CAS is 500-22-1. Through research, I have a further understanding and discovery of 3-Pyridinecarboxaldehyde
Highly effective and safe drugs for the treatment of neuropathic pain are urgently required and it was shown that blocking T-type calcium channels can be a promising strategy for drug development for neuropathic pain. We have developed pyrrolidine-based T-type calcium channel inhibitors by structural hybridization and subsequent assessment of in vitro activities against Ca(v)3.1 and Ca(v)3.2 channels. Profiling of in vitro ADME properties of compounds was also carried out. The representative compound 17h showed comparable in vivo efficacy to gabapentin in the SNL model, which indicates T-type calcium channel inhibitors can be developed as effective therapeutics for neuropathic pain.
About 3-Pyridinecarboxaldehyde, If you have any questions, you can contact Son, WS; Jeong, KS; Lim, SM; Pae, AN or concate me.. SDS of cas: 500-22-1
Reference:
Pyridine – Wikipedia,
,Pyridine | C5H5N – PubChem